DFTX Q4 2025 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$48M

Net Income

-$50M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$73M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$440M

Total Liabilities

$108M

Stockholders' Equity

$332M

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$48M	-$32M	-46.6%
Net Income	-$50M	-$35M	-45.2%